Since becoming an independent company in 2023, Simtra BioPharma Solutions, a CDMO specializing in sterile injectables, has executed a strategic plan that includes nearly half a billion dollars in projects, major site expansions and the establishment of development services to better integrate early-stage and commercial manufacturing.

Last year, Simtra accelerated its growth across North America and Europe to meet growing demand for complex, high-value therapies. In the United States at its site in Bloomington, Indiana, it purchased a flexible clinical line for pre-filled syringes and liquid and lyophilized vials and began construction of new production facility that will house three isolator commercial-scale sterile filling lines. The company also acquired a 65-acre property nearby with more than 300,000 square feet of available space for future development, including the installation of at least six additional isolator filling lines.

Simultaneously, Simtra’s expansion in Halle/Westfalen, Germany continued with the addition of a new conjugation and purification suite and the inauguration of a new building with two new high-speed isolator lines: one for syringes and one for liquid and lyophilized vials.

Contract Pharma caught up with Franco Negron, CEO of Simtra BioPharma Solutions, at DCAT Week to discuss the company’s strategic expansion, the market forces behind Simtra’s growth, automation, AI, workforce development and more.

Executing on a Clear Strategy

Negron characterizes Simtra’s last twelve to eighteen months as “very intense but successful.”

“When our sponsors acquired the company from Baxter International, Inc, there was a clear strategy in place, and we began executing immediately,” Negron says.

Bloomington and Halle were both well-established sites when they were acquired. Halle had just completed an expansion that increased prefilled syringe and lyophilization capacity. In Bloomington, market demand required additional capacity, so Simtra invested $250 million in new isolator-based lines and other upgrades.

For development services, Halle was better positioned initially because its infrastructure supports smaller batches. Bloomington historically had high-speed, high-volume equipment, so Simtra purchased a new line specifically for development work, including lyophilizers and related equipment.

The next step was enabling interchangeability for customers — and the market’s top priority was high potency manufacturing. That’s why Simtra purchased the Park facility: 65 acres and 300,000 square feet of pharma grade space, essentially ready to go.

According to Negron, Simtra has already installed three lyos, and a high potency line arrives in the coming weeks at the Park facility. It will be operational in North America by late next year. This mirrored capability is important for customers, for regional supply resilience, and for post COVID expectations.

Why Now: Market Forces Behind Simtra’s Growth

Negron cites very strong market fundamentals as a factor that influenced its decision to invest when it did.

“Biologics continue to grow, and I was excited about the assets in Halle and our bioconjugation capabilities. Combined with the backing of two top private equity firms willing to invest early — which is essential in this business — the timing was ideal,” says Negron.

“There is also a broader motivation,” he adds. “Contributing to bringing new therapies to patients worldwide. This was the right moment to create another scaled, high-quality option for the market.”

With so many CDMOs investing heavily right now, Negron believes three things differentiate Simtra from the competition:

• Leadership in high potency drugs: Simtra’s Halle site manufactures the majority of commercial ADCs on the market. Very few companies have that capability. And now Simtra is building high potency capacity in North America as well, which will strengthen its position.
• Scale and expertise in sterile injectables: Bloomington is one of the world’s largest producers of prefilled syringes. The team has decades of experience and a strong reputation for quality and reliability. While some competitors may have more lines, Simtra’s lines include high potency capabilities others do not.
• A culture of continuous improvement: “Many companies talk about it; we demonstrate it,” says Negron. Some customers have doubled their volumes in a single year because Simtra could support them. The company also maintains strong relationships with global regulatory agencies.

“We bring 65 years of experience,” Negron stresses. “We didn’t just show up. We have a long, proven history.”

Investing in New Technology

All of Simtra’s new filling lines use isolators, automation, and state of the art designs. The company is also investing in faster, more efficient changeovers — essential when you run many different products.

Additionally, Negron emphasizes the focused, value-driven approach Simtra is taking to artificial intelligence (AI). Places where AI is being utilized include:

• Training: Operators in sterile environments must master precise movements. Simtra uses cameras connected to AI that instantly alert them if they move too fast or deviate from SOPs — providing consistent, objective feedback.
• Development: Simtra generates huge amounts of data from lyophilization and other processes. AI can detect patterns, optimize cycles, and even help Simtra move toward long term goals like reducing the length of lyophilization when feasible.
• Quality and documentation: AI can analyze deviation histories and suggest more effective corrective and preventive actions. This shifts the focus from remediation to true optimization.

“Our goal is not to replace people but to improve outcomes, strengthen customer service, and develop our workforce,” says Negron.

Workforce Development

Developing and retaining specialized sterile-injectables talent is an important part of innovation at Simtra, so the company emphasizes workforce development in several ways.

“First, we’re enhancing training so people feel confident and skilled, which is critical in sterile manufacturing,” Negron remarks.

“Second, we compensate these roles well. People with the ability to run sterile lines are extremely valuable, and we don’t want to lose them over small salary differences.

“Third, leadership development. We rolled out leadership training to 100% of employees, not just supervisors. Everyone contributes to leadership at their level, and we want people to feel empowered, supported, and aligned with a clear vision.

“And finally, we focus on creating a workplace people enjoy. Compensation matters, but culture — feeling respected, purposeful, and recognized — is what keeps people here.”

Looking Ahead

Looking ahead to 2030 and beyond, Negron envisions an injectable supply chain built on redundancy, technological innovation, and extensive automation supported by AI.

Above all else, Simtra’s foundational mission—bringing critical sterile injectable medicines to patients—continues to guide its investments, operations, and culture.

“It all comes down to our people,” Negron emphasizes. “Our teams in Halle and Bloomington have faced an extraordinary amount of change in a short period, and they continue to rise to the challenge. They deserve tremendous appreciation.”